Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

CRSwNP Phase 2 program is the first multi-national Phase 2 trial with a TSLP pathway inhibitor to explore every-12-week dosing. WALTHAM, Mass. – January 3, 2024 – Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the dosing of the first patients in a Phase 2 clinical trial of verekitug […] The post Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) appeared first on Upstream Bio .